Durect

Country

Ownership: -

Employees: 58

Market Cap: -

Website

Introduction: DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Clinical Trials

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Phase 2

Completed

Conditions: Alcoholic Hepatitis

Interventions: Drug: DUR-928 30 mg
Drug: DUR-928 90 mg
Drug: Placebo+ Standard of Care (SOC)

First Posted Date: 2020-09-24

Last Posted Date: 2024-02-26

Lead Sponsor: Durect

Target Recruit Count: 307

Registration Number: NCT04563026

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 65 locations

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

Phase 2

Terminated

Conditions: SARS-CoV-2

Interventions: Drug: DUR-928
Drug: Placebo

First Posted Date: 2020-06-25

Last Posted Date: 2022-08-05

Lead Sponsor: Durect

Target Recruit Count: 2

Registration Number: NCT04447404

Locations: 🇺🇸
Site 03, Newark, New Jersey, United States

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: DUR-928 Topical Solution
Drug: Vehicle Topical Solution

First Posted Date: 2019-02-12

Last Posted Date: 2022-09-02

Lead Sponsor: Durect

Target Recruit Count: 25

Registration Number: NCT03837743

Locations: 🇺🇸
Site 05, Tampa, Florida, United States
🇺🇸
Site 02, Plainfield, Indiana, United States
🇺🇸
Site 03, Spokane, Washington, United States

and more 2 locations

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Phase 2

Completed

Conditions: Alcoholic Hepatitis

Interventions: Drug: DUR-928 150 mg
Drug: DUR-928 30 mg
Drug: DUR-928 90 mg

First Posted Date: 2018-02-14

Last Posted Date: 2022-12-14

Lead Sponsor: Durect

Target Recruit Count: 19

Registration Number: NCT03432260

Locations: 🇺🇸
DURECT Study Site 0004, Atlanta, Georgia, United States
🇺🇸
DURECT Study Site 0002, Chicago, Illinois, United States
🇺🇸
DURECT Study Site 0005, Louisville, Kentucky, United States

and more 4 locations

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Phase 2

Terminated

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: DUR-928

First Posted Date: 2018-01-09

Last Posted Date: 2022-10-17

Lead Sponsor: Durect

Target Recruit Count: 5

Registration Number: NCT03394781

Locations: 🇺🇸
Charlotte Mecklenburg Hospital, Charlotte, North Carolina, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
Southern Therapy and Advanced Research, Jackson, Mississippi, United States

and more 1 locations

Trial of Extended Release Bupivacaine for Pain Relief After Surgery

Phase 3

Completed

Conditions: Post Operative Pain

Interventions: Drug: SABER-Bupivacaine (Part 1)
Drug: SABER-Bupivacaine (Part 2)
Drug: Saline Placebo
Drug: Bupivacaine HCl

First Posted Date: 2015-10-14

Last Posted Date: 2021-07-13

Lead Sponsor: Durect

Target Recruit Count: 399

Registration Number: NCT02574520

Locations: 🇺🇸
Durect Study Site 04, Florence, Alabama, United States
🇺🇸
Durect Study Site 03, Sheffield, Alabama, United States
🇺🇸
Durect Study Site 15, Fontana, California, United States

and more 18 locations

An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery

Completed

Conditions: Pain

First Posted Date: 2010-06-09

Last Posted Date: 2022-06-15

Lead Sponsor: Durect

Target Recruit Count: 47

Registration Number: NCT01139866

Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

Phase 2

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: Bupivacaine TTS (Bupivacaine Patch)
Drug: Placebo patch

First Posted Date: 2010-03-31

Last Posted Date: 2022-06-15

Lead Sponsor: Durect

Target Recruit Count: 263

Registration Number: NCT01096966

Bupivacaine Effectiveness and Safety in SABER® Trial

Phase 3

Completed

Conditions: Postoperative Pain
Abdominal Surgery

Interventions: Drug: SABER-Bupivacaine
Drug: SABER-Placebo
Drug: Bupivacaine HCl

First Posted Date: 2010-01-20

Last Posted Date: 2021-06-01

Lead Sponsor: Durect

Target Recruit Count: 331

Registration Number: NCT01052012

Locations: 🇳🇿
DURECT Study Site, Christchurch, New Zealand

An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery

Phase 2

Completed

Conditions: Postoperative Pain

Interventions: Drug: Bupivacaine HCl Treatment 1c
Drug: SABER-Bupivacaine Treatment 2a
Drug: Placebo SABER-Bupivacaine Treatment 2b
Drug: SABER-Bupivacaine Treatment 1a
Drug: Bupivacaine HCl Treatment 2c
Drug: Placebo SABER-Bupivacaine Treatment 1b

First Posted Date: 2009-10-12

Last Posted Date: 2021-06-09

Lead Sponsor: Durect

Target Recruit Count: 107

Registration Number: NCT00993798

Locations: 🇸🇪
Nycomed Investigational Site, Stockholm, Sweden

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy